Analysts Offer Predictions for Equillium FY2029 Earnings

Equillium, Inc. (NASDAQ:EQ) – Investment analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for Equillium in a report issued on Friday, March 28th. Leerink Partnrs analyst T. Smith anticipates that the company will earn ($0.06) per share for the year. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Equillium’s current full-year earnings is $0.14 per share.

Separately, Leerink Partners reiterated a “market perform” rating and set a $1.00 price objective (down previously from $3.00) on shares of Equillium in a research note on Friday.

Equillium Price Performance

NASDAQ EQ opened at $0.39 on Monday. Equillium has a 1 year low of $0.36 and a 1 year high of $2.43. The company has a market capitalization of $13.90 million, a PE ratio of -2.80 and a beta of 1.87. The company has a fifty day moving average of $0.75 and a 200 day moving average of $0.79.

Equillium (NASDAQ:EQ) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.06. Equillium had a negative net margin of 10.05% and a negative return on equity of 20.68%. The business had revenue of $4.39 million for the quarter.

Institutional Investors Weigh In On Equillium

A hedge fund recently bought a new stake in Equillium stock. Takeda Pharmaceutical Co. Ltd. bought a new stake in shares of Equillium, Inc. (NASDAQ:EQ) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 1,824,977 shares of the company’s stock, valued at approximately $1,369,000. Equillium accounts for about 5.2% of Takeda Pharmaceutical Co. Ltd.’s portfolio, making the stock its 4th largest position. Takeda Pharmaceutical Co. Ltd. owned approximately 5.15% of Equillium as of its most recent SEC filing. 27.05% of the stock is currently owned by institutional investors.

About Equillium

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.